326 related articles for article (PubMed ID: 11955527)
1. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment.
Moreno MJ; Abounader R; Hébert E; Doods H; Hamel E
Neuropharmacology; 2002 Mar; 42(4):568-76. PubMed ID: 11955527
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of CGRP receptors in the human isolated middle meningeal artery.
Gupta S; Mehrotra S; Avezaat CJ; Villalón CM; Saxena PR; Maassenvandenbrink A
Life Sci; 2006 Jun; 79(3):265-71. PubMed ID: 16458930
[TBL] [Abstract][Full Text] [Related]
3. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells.
Edvinsson L; Alm R; Shaw D; Rutledge RZ; Koblan KS; Longmore J; Kane SA
Eur J Pharmacol; 2002 Jan; 434(1-2):49-53. PubMed ID: 11755165
[TBL] [Abstract][Full Text] [Related]
4. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation.
Petersen KA; Lassen LH; Birk S; Lesko L; Olesen J
Clin Pharmacol Ther; 2005 Mar; 77(3):202-13. PubMed ID: 15735614
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity.
Gupta S; Mehrotra S; Villalón CM; Garrelds IM; de Vries R; van Kats JP; Sharma HS; Saxena PR; Maassenvandenbrink A
Eur J Pharmacol; 2006 Jan; 530(1-2):107-16. PubMed ID: 16375887
[TBL] [Abstract][Full Text] [Related]
6. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats.
Arulmani U; Schuijt MP; Heiligers JP; Willems EW; Villalón CM; Saxena PR
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):291-7. PubMed ID: 15228501
[TBL] [Abstract][Full Text] [Related]
7. Noncompetitive antagonism of BIBN4096BS on CGRP-induced responses in human subcutaneous arteries.
Sheykhzade M; Lind H; Edvinsson L
Br J Pharmacol; 2004 Dec; 143(8):1066-73. PubMed ID: 15477223
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat.
Petersen KA; Birk S; Doods H; Edvinsson L; Olesen J
Br J Pharmacol; 2004 Nov; 143(6):697-704. PubMed ID: 15504760
[TBL] [Abstract][Full Text] [Related]
9. The tortuous road to an ideal CGRP function blocker for the treatment of migraine.
Davis CD; Xu C
Curr Top Med Chem; 2008; 8(16):1468-79. PubMed ID: 18991732
[TBL] [Abstract][Full Text] [Related]
10. BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37).
Verheggen R; Bumann K; Kaumann AJ
Br J Pharmacol; 2002 May; 136(1):120-6. PubMed ID: 11976276
[TBL] [Abstract][Full Text] [Related]
11. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat.
Storer RJ; Akerman S; Goadsby PJ
Br J Pharmacol; 2004 Aug; 142(7):1171-81. PubMed ID: 15237097
[TBL] [Abstract][Full Text] [Related]
12. Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity.
Wu D; Doods H; Arndt K; Schindler M
Biochem Soc Trans; 2002 Aug; 30(4):468-73. PubMed ID: 12196117
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.
Doods H; Hallermayer G; Wu D; Entzeroth M; Rudolf K; Engel W; Eberlein W
Br J Pharmacol; 2000 Feb; 129(3):420-3. PubMed ID: 10711339
[TBL] [Abstract][Full Text] [Related]
14. Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks.
Edvinsson L
CNS Drug Rev; 2005; 11(1):69-76. PubMed ID: 15867953
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery.
Edvinsson L; Nilsson E; Jansen-Olesen I
Br J Pharmacol; 2007 Mar; 150(5):633-40. PubMed ID: 17245362
[TBL] [Abstract][Full Text] [Related]
16. Pain pharmacology in migraine: focus on CGRP and CGRP receptors.
Benemei S; Nicoletti P; Capone JA; Geppetti P
Neurol Sci; 2007 May; 28 Suppl 2():S89-93. PubMed ID: 17508187
[TBL] [Abstract][Full Text] [Related]
17. Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig.
Kapoor K; Arulmani U; Heiligers JP; Willems EW; Doods H; Villalón CM; Saxena PR
Eur J Pharmacol; 2003 Aug; 475(1-3):69-77. PubMed ID: 12954361
[TBL] [Abstract][Full Text] [Related]
18. BIBN4096BS and CGRP(8-37) antagonize the relaxant effects of alpha-CGRP more than those of beta-CGRP in human extracranial arteries.
Verheggen R; Wojtas K; Webel M; Hoffmann S; Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 2005 May; 371(5):383-92. PubMed ID: 15983761
[TBL] [Abstract][Full Text] [Related]
19. The preclinical pharmacology of BIBN4096BS, a CGRP antagonist.
Hay DL; Poyner D
Cardiovasc Drug Rev; 2005; 23(1):31-42. PubMed ID: 15867946
[TBL] [Abstract][Full Text] [Related]
20. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow.
Tröltzsch M; Denekas T; Messlinger K
Eur J Pharmacol; 2007 May; 562(1-2):103-10. PubMed ID: 17349622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
